TONIX PHARMACEUTICALS HOLDING CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $368197.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $837519.00, a 99.93% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $1211637627.00, a 1847008477.74% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $65.60, a 14.23% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $76.48, a 95.64% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $833637.00, a 99.71% decline from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $288965154.00, a 80590.15% increase from fiscal 2023.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $358117.00, a 4247.10% increase from fiscal 2022.
- TONIX PHARMACEUTICALS HOLDING CORP. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $8238.07, a 94.50% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $368197.00 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | $837519.00 10-Q · filed 2026-05-11 | ||||
| 2025-12-31 | $833637.00 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $1895690.00 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $1102887011.00 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | $1211637627.00 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $288965154.00 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $34586.33 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $42044.88 10-Q · filed 2024-08-16 | ||||
| 2024-03-31 | $65.60 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $358117.00 10-K · filed 2025-03-18 | $345.92 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $453.81 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $874.50 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $76.48 10-Q · filed 2023-05-08 | ||||
| 2022-12-31 | $8238.07 10-K · filed 2024-04-01 | $255.40 10-K · filed 2023-03-13 | |||
| 2022-09-30 | $267.12 10-Q · filed 2022-11-07 | ||||
| 2022-06-30 | $381.16 10-Q · filed 2022-08-08 | ||||
| 2022-03-31 | $1755.85 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $149713.14 10-K · filed 2023-03-13 | $2155.81 10-K · filed 2022-03-14 | |||
| 2021-09-30 | $2032.78 10-Q · filed 2021-11-08 | ||||
| 2021-06-30 | $2937.37 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $2937.37 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $359.86 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | $359.86 10-Q · filed 2019-11-08 | ||||
| 2019-06-30 | $35.42 10-Q · filed 2019-08-12 | ||||
| 2019-03-31 | $35.42 10-Q · filed 2019-05-13 | ||||
| 2018-12-31 | $388.44 10-K · filed 2020-03-24 | $38.75 10-K · filed 2019-03-18 | |||
| 2017-12-31 | $670.36 10-K · filed 2019-03-18 | $67.04 10-K · filed 2018-03-09 | |||
| 2017-09-30 | $104.55 10-Q · filed 2017-11-06 | ||||
| 2017-06-30 | $110.29 10-Q · filed 2017-08-11 | ||||
| 2016-12-31 | $57.00 10-K · filed 2018-03-09 | ||||
| 2016-09-30 | $5.52 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $6.17 10-Q · filed 2016-08-05 | ||||
| 2015-12-31 | $81.67 10-K · filed 2017-04-13 | ||||
| 2012-12-31 | $30.00 10-K · filed 2014-03-28 | $1.50 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |